Measurement of visceral fat for early prediction of prediabetes—Cross-sectional study from Southern India

Jadhav, Radhika; Maiya, Arun G.; Shivashankara, KN; Umakanth, Shashikiran

doi:10.1016/j.jtumed.2022.05.006

Cited by 3 publications

(2 citation statements)

References 43 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 12 A cross-sectional study in India reported that visceral fat measurement can be used for predicting prediabetes. 13 Additionally, the prognostic risk of diabetic kidney disease progression in T2DM patients was shown to be positively correlated with VFA. 14 Another study in T1DM patients found that VFA is associated with coronary artery calcification and cardiac dysfunction.…”

Section: Discussionmentioning

confidence: 96%

Serum Uric Acid to High‑density Lipoprotein Cholesterol Ratio is Associated with Visceral Fat in Patients with Type 2 Diabetes

Sun¹,

Hong²,

Ruan³

et al. 2023

DMSO

View full text Add to dashboard Cite

To determine whether the uric acid/high-density lipoprotein cholesterol ratio (UHR) is associated with visceral fat area (VFA) in patients with type 2 diabetes mellitus (T2DM). Methods: Participants aged 18-70 years with a diagnosis of T2DM were recruited from the National Metabolic Management Center from January 2020 to July 2022. Medical data collected for all participants included medical history, general measures, carotid intimamedia thickness, abdominal VFA, and subcutaneous fat area (SFA). The participants were divided into groups according to VFA ≥100 cm 2 (n=109) and VFA <100 cm 2 (n=100). Results: Compared with the VFA <100 cm 2 group, the VFA ≥100 cm 2 group had higher height, weight, body mass index (BMI), waist circumference (WC), hip circumference (HC), SFA, fasting plasma glucose, fasting insulin, C peptide, homeostatic model assessment of insulin resistance (HOMA-IR), alanine transaminase (ALT), aspartate transaminase, γ-glutamine acyltransferase (γ-GGT), uric acid (UA), triglyceride (TG), and UHR measurements and lower high-density lipoprotein cholesterol (HDL-C) (P<0.05). No significant difference was observed between the groups for age, duration of T2DM, diastolic blood pressure, systolic blood pressure, IMT, glycosylated hemoglobin, total cholesterol, and low-density lipoprotein cholesterol. Positive correlations were found between the UHR and height, weight, BMI, WC, HC, C peptide, ALT, γ-GGT, TG, and UA, as well as between VFA and these variables (P<0.05). Both the UHR and VFA were negatively correlated with HDL-C (P<0.05). Positive correlations were observed between VFA and the UHR as well as UA (P<0.05), and a negative correlation was found between VFA and HDL-C (P<0.05). Multivariate linear stepwise regression identified BMI, WC, UHR, SFA, and HC as influencing factors for VFA (P<0.05). Conclusion: UHR was positively associated with VFA in T2DM patients and may be a useful and convenient additional tool for metabolic risks in these patients.

show abstract

Section: Discussionmentioning

confidence: 96%

Serum Uric Acid to High‑density Lipoprotein Cholesterol Ratio is Associated with Visceral Fat in Patients with Type 2 Diabetes

Sun¹,

Hong²,

Ruan³

et al. 2023

DMSO

View full text Add to dashboard Cite

show abstract

“…In the same way, there is evidence that alterations in DNA methylation can contribute to the increased prevalence of obesity and both type 1 (T1D) and T2D [ 16 ]. Visceral fat (VF) is known to be associated with prediabetes and insulin resistance [ 17 ], and lipids secreted from obese adipose tissue accumulate in peripheral tissues such as the liver, pancreas, and muscle and alter insulin sensitivity causing T2D [ 18 ]. Studies included in a 2019 review have reported an epigenetic association with obesity, particularly with altered BMI and waist circumference, reporting differential DNA methylation and increased epigenetic variability in obese people [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

Epigenetics in Obesity and Diabetes Mellitus: New Insights

et al. 2023

View full text Add to dashboard Cite

A long-term complication of obesity is the development of type 2 diabetes (T2D). Patients with T2D have been described as having epigenetic modifications. Epigenetics is the post-transcriptional modification of DNA or associated factors containing genetic information. These environmentally-influenced modifications, maintained during cell division, cause stable changes in gene expression. Epigenetic modifications of T2D are DNA methylation, acetylation, ubiquitylation, SUMOylation, and phosphorylation at the lysine residue at the amino terminus of histones, affecting DNA, histones, and non-coding RNA. DNA methylation has been shown in pancreatic islets, adipose tissue, skeletal muscle, and the liver. Furthermore, epigenetic changes have been observed in chronic complications of T2D, such as diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy. Recently, a new drug has been developed which acts on bromodomains and extraterminal (BET) domain proteins, which operate like epigenetic readers and communicate with chromatin to make DNA accessible for transcription by inhibiting them. This drug (apabetalone) is being studied to prevent major adverse cardiovascular events in people with T2D, low HDL cholesterol, chronic kidney failure, and recent coronary events. This review aims to describe the relationship between obesity, long-term complications such as T2D, and epigenetic modifications and their possible treatments.

show abstract

Effect of a Customized Physical Activity Promotion Program on Visceral Fat and Glycemic Parameters in Individuals With Prediabetes: A Randomized Controlled Trial

Jadhav,

Maiya,

Umakanth

et al. 2024

Journal of Physical Activity and Health

View full text Add to dashboard Cite

Background: Physical activity of any amount results in substantial health benefits. However, public awareness of physical activity benefits in chronic diseases is inadequate in India. Prediabetes is a significant health issue on a global scale. Visceral fat (VF) is considered as an early predictor of prediabetes. Ethnicity and race have a substantial impact on VF. Hence, this study intended to evaluate the effect of a customized physical activity promotion program on VF and glycemic parameters in individuals with prediabetes. Methods: In the current, parallel group randomized controlled trial, a total of 158 participants were recruited: 79 in intervention and 79 in control group. The study included the prediabetes individuals based on American Diabetes Association criteria. Participants from the intervention group received the customized physical activity promotion program for 24 weeks. The primary outcome measures of the study were VF level and glycemic parameters that included fasting blood sugar and glycosylated hemoglobin. Two-way mixed analysis of variance was used to study the mean difference of an outcome between 2 groups over time. Results: The study found a statistically significant interaction between the intervention and times on VF level, F1,136 = 23.564, fasting blood sugar levels, F1,136 = 8.762, and glycosylated hemoglobin levels, F1,136 = 64.582 at the end of 24 weeks (P < .05). Conclusions: This study concluded that a customized physical activity promotion program was effective in reducing VF in individuals with prediabetes as compared with controls. It improved glycemic control by reducing fasting blood sugar and glycosylated hemoglobin levels.

show abstract

Measurement of visceral fat for early prediction of prediabetes—Cross-sectional study from Southern India

Cited by 3 publications

References 43 publications

Serum Uric Acid to High‑density Lipoprotein Cholesterol Ratio is Associated with Visceral Fat in Patients with Type 2 Diabetes

Serum Uric Acid to High‑density Lipoprotein Cholesterol Ratio is Associated with Visceral Fat in Patients with Type 2 Diabetes

Epigenetics in Obesity and Diabetes Mellitus: New Insights

Effect of a Customized Physical Activity Promotion Program on Visceral Fat and Glycemic Parameters in Individuals With Prediabetes: A Randomized Controlled Trial

Contact Info

Product

Resources

About